Citations

Clear

186 citation(s) found for "Frantz, R".

Male Survival Disadvantage in Pulmonary Hypertension in the PVRI Godeep Meta-registry
Annis, Jeffrey , Meike, F., Wilhelm, Jochen , Kiely, David G. , Balasubramanian, A., Eichstaedt, Christina A. , Zamanian, Roham T. , Elwing, Jean , Pepke-Zaba, J., Hernandez, Nadia , Frauendorf, Marlize , Williams, Paul , Anthi, Anastasia , Dima, Efrossini, Majeed, Rehan, Tello, Khodr , Kiely, David , Yogeswaran, Athiththan , Howard, Luke , Lawrie, Allan , Wilkins, Martin R. , Balasubramanian, A. , Hassoun, Paul M. , Grünig, Ekkehard , Sweatt, Andrew J. , Kovács, Gábor , Olschewski, Horst , Ghouleh, Imad Al , Chan, Stephen Y. , Jose, Arun , Cannon, J., Pepke-Zaba, J., Frantz, Robert P. , Sіrenko, Yu.M. , Torbas, O.O. , Sahay, Sandeep , Hernandez, N., Arvanitaki, Alexandra , Giannakoulas, George , Sabbour, Hani Mohamed , Saleh, Khaled Musa Mohammad , Ghio, Stefano , Scelsi, Laura , Majeed, R., Ghofrani, Hossein Ardeschir , Grimminger, Friedrich , Cajigas, Héctor , Brittain, Evan L , Seeger, Werner

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7097-A7097

10.1164/ajrccm.2025.211.abstracts.a7097 Get It

Abstract Introduction Sex-based differences in morbidity and mortality for pulmonary hypertension (PH) are insufficiently addressed in current research. However, recognizing these differences is crucial for optimal clinical management and improving outcomes. This study assesses the effect of sex on survival among PH patients, while accounting for disease severity, comorbidities, treatment, and race. Methods We analyzed data from the PVRI GoDeep meta-registry, including all incident patients with complete hemodynamic profiles. Survival was evaluated using Kaplan-Meier and Cox proportional hazards models, adjusted for various confounders. Analyses included both PAH and non-PAH groups and risk assessment by the ESC/ERS 2022, REVEAL lite 2, and COMPERA 4-strata scores. All analyses were performed using R (The R Foundation). Results A total of 19,663 incident PH patients were included in the analysis, with 5,581 patients (28%) diagnosed with Group 1 PH and a median age of 64 years [IQR: 52-73]. Among these, male patients (8,704, 44%) had a significantly higher mortality risk than female patients across the entire cohort and within all PH subtypes. The adjusted hazard ratio for mortality in male versus female patients was 1.391 [95% CI: 1.260-1.536] in the overall population and 1.404 [95% CI: 1.264-1.561] for those with PAH. This survival difference was consistent across various severity levels, age groups, and in the presence of comorbidities such as obesity and cardiovascular diseases, as well as among those receiving PAH-specific therapies as well as patients who remained without treatment during the observation period. Notably, male disadvantage in survival was observed in low, intermediate, and high-risk categories for ESC/ERS 2022, REVEAL lite 2, and COMPERA scores but not within REVEAL 2.0, which includes male sex as a non-modifiable risk factor. Racial analysis revealed a greater mortality risk for males among White patients, with no significant differences noted in Black or Asian populations. Conclusion Our PVRI GoDeep meta-registry analysis demonstrates that male PH patients face higher mortality risk across both PAH and non-PAH groups, independent of disease etiology, age, severity, comorbidities, and treatment factors, with this risk amplified in White patients. These findings suggest that male sex should be further considered as a risk factor to refine predictive models for survival in PH.
A Challenging Diagnosis: When to Suspect Pulmonary Veno-occlusive Disease
Lee, James , Jokhadar, Maan , Frantz, Robert P.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A6476-A6476

10.1164/ajrccm.2025.211.abstracts.a6476 Get It

Abstract INTRODUCTION: Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) is a rare subgroup of pulmonary arterial hypertension (PAH). Unfortunately, there is significant overlap between PVOD and PAH, making differentiation difficult. Thus, a constellation of investigations is necessary to suggest such a diagnosis. CASE PRESENTATION: A 65-year-old female with a history of smoking was diagnosed with idiopathic PAH following 2 months of worsening dyspnea. Right heart catheterization (RHC) revealed a mean PA pressure (mPAP) 58mmHg, pulmonary artery wedge pressure (PAWP) 14mmHg, cardiac output/index (CO/CI) 5.5/2.6, and pulmonary vascular resistance (PVR) 8 Wood units. Further workup excluded other causes of pulmonary hypertension (Table 1). Tadalafil was initially started followed by macitentan, which were associated with worsening hypoxemia and dyspnea. Computed tomography (CT) scan of the chest revealed mediastinal lymphadenopathy and small bilateral pleural effusions. This development in relation to the initiation of PAH-directed therapies raised concern for possible PVOD. Medical therapy was downtitrated, but worsening hypoxemia in the setting of worsening edema led to the cessation of all therapies. Due to clinical concern, the patient was admitted for a repeat RHC and close supervision during a trial of epoprostenol. RHC revealed a mPAP of 57mmHg, PAWP 5mmHg, CO/CI 3.4/1.6 and PVR 15 Wood units. She had been on metoprolol for hypertension which was discontinued. Low-dose epoprostenol was started at 1ng/kg/min. Her oxygen requirements increased slightly which improved with diuresis. Epoprostenol was slowly titrated with improvements in CI. Repeat chest CT showed mild diffuse centrilobular nodular opacities more prominent compared to prior scans, and adenopathy. After a steady dose of epoprostenol (4ng/kg/min), the patient improved with lower oxygen requirements. She was discharged with plans to continue low dose outpatient epoprostenol and start sotatercept. Lung transplant evaluation is on hold pending response to this approach. Genetic testing is pending. DISCUSSION: Despite challenges of definitive diagnosis where lung biopsy is risky, a diagnosis of PVOD can be supported from a spectrum of strongly suggestive clinical, hemodynamic and radiographic features. Though genetic testing for the EIF2AK4 mutation may confirm the presence of heritable PVOD, its absence does not exclude its possibility as most cases do not have an identifiable genetic cause. Management is challenging given ineffective or potentially harmful responses to PAH-directed therapies, though some do respond to a variable extent. As suggested here, close supervision during epoprostenol infusion adds to the limited body of evidence supporting such endeavors when initiating vasodilatory therapies in patients with suspected PVOD.
Assessing the Utility of Provocative Maneuvers During Right Heart Catheterization in Pulmonary Venous Hypertension
Mendoza, Marco Patricio Bravo, Reddy, Yogesh N.V. , Hassoun, P.M., Hill, Nicholas S. , Erzurum, Serpil C. , Beck, Gerald J. , Finet, Emanuel, Jellis, C.L., Mathai, Stephen C. , Nishimura, Rick , Mathai, Stephen C , Frantz, Robert P. , Hassoun, P.M., Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rosenzweig, Erika B. , Mehra, Reena , Borlaug, Barry A. , Rischard, Franz

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3283-A3283

10.1164/ajrccm.2025.211.abstracts.a3283 Get It

Abstract Rationale: Although guidelines recommend the use of provocative testing to diagnose pulmonary venous hypertension (PVH) that is unapparent at normal resting right heart catheterization (RHC), the incremental value of provocative testing is unknown. We aim to evaluate the incremental diagnostic capability of inhaled nitric oxide (iNO), fluid challenge (FC) or invasive cardiopulmonary exercise testing (iCPET) to unmask PVH using previously defined hemodynamic cutoffs. Methods: We included subjects from the NHLBI-funded Pulmonary Vascular Disease Phenomics (PVDOMICS) study. Our analysis included patients with World Symposium on Pulmonary Hypertension (WSPH) Group 2 disease (G2PH) and G2PH comparators (WSPH Group 2 phenotype without a diagnosis of PH) as determined by the PI or adjudication panel. We then applied a protocol-driven provocative approach based on the feasibility of modalities available in most catheterization labs. Using a pulmonary capillary wedge pressure (PCWP) cutoff of >15, frequencies were identified for subjects based on resting PCWP and with iNO. Frequencies were also identified for: those who received FC with a PCWP cutoff of ≥18 or those who received iCPET with PCWP cutoff of >20 (upright) or >25 (supine). Results: There were 419 subjects identified with WSPH Group 2 disease (Figure). Roughly half were found to have a PCWP >15 during resting RHC (N = 207). Of the remaining subjects with a resting PCWP ≤15 (N = 150), 42 subjects were found to have a PCWP >15 with iNO administration (40.0%). Of the remaining 63 subjects with PCWP ≤15 following iNO administration, nearly half (N = 26, 48.0%) demonstrated a PCWP ≥18 following FC while 8 subjects (14.8%) demonstrated an elevated PCWP following iCPET. Conclusions: There is a high proportion of G2PH patients (∼35%) who appear hemodynamically similar to precapillary PH at rest. Inhaled nitric oxide vasodilatory challenge unmasks G2PH in many patients. In situations where iNO does not disclose the G2PH phenotype, provocation with FC or iCPET can be useful as a supplementary provocative maneuver. Future directions will focus on agnostically assessing the utility of provocation based on grouping subjects by resting hemodynamics as well as assessing the use of provocation in other forms of PH.
Association of Pulmonary Artery Dilation With Pulmonary Artery Pressure and Survival Using Updated Pulmonary Hypertension Hemodynamic Criteria
Couch, Taylor , Beck, Gerald J. , Erzurum, Serpil C. , Hill, Nicholas S. , Lempel, Jason K. , Nian, Hui , Schwalbach, Kevin T. , Terry, J.G., Group, The PVDOMICS Study, Rosenzweig, Erika B. , Carr, J. Jeffrey , Frantz, Robert P. , Hassoun, Paul M. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Hemnes, Anna R. , Group, The PVDOMICS Study

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3279-A3279

10.1164/ajrccm.2025.211.abstracts.a3279 Get It

Abstract Rationale: Prior studies report association between pulmonary artery (PA) dilation on computed tomography (CT) imaging and pulmonary hypertension (PH). These studies predate expansion of PH hemodynamic diagnostic criteria and do not report patient mortality. As such, little is known about the presence of vascular changes in mild PH or their association with survival. We sought to investigate these relationships in individuals without significant parenchymal lung disease. Methods: We obtained CT images for subjects with group 1 or 2 PH, disease comparators, and healthy controls enrolled in the Pulmonary Vascular Disease Phenomics (PVDOMICS) study. We used Osirix imaging software to measure the main, left, and right PA (MPA, LPA, and RPA) and MPA:aorta (PA:Ao) ratio by diameter and cross-sectional area at locations consistent with prior studies. We evaluated associations with mortality and mean PA pressure (mPAP) using multivariable Cox and linear regression models adjusting for age, sex, and BMI. Descriptive statistics are presented as mean ± SD. Results: We identified 558 subjects (59 controls, 138 comparators, and 361 PH [267 group 1, 94 group 2]). 79 subjects had mPAP < 21 mmHg, 39 had mPAP 21-24 mmHg, and 371 had mPAP ≥ 25 mmHg. Increased MPA, LPA, and RPA diameter and area, PA:Aodia, and PA:Aoarea were associated with decreased survival (all p < 0.001) after multivariable adjustment. First versus third quantiles of all measurements were associated with mortality, with adjusted hazard ratio of 2.99 [95% CI 1.77, 5.05] for MPA diameter (2.84 vs 3.82 cm), 3.74 [2.07, 6.74] for MPA area (7.26 vs 12.74 cm2) and 5.24 [2.58, 10.66] for LPA area (4.55 vs 7.03 cm2). All measures significantly increased alongside PH severity from mPAP < 20 to 21-24 to ≥ 25 mmHg (see figure 1 for MPA diameter). All measures positively correlated with mPAP, including MPA diameter (ρspearman = 0.55) and PA:Aodia (ρ = 0.56). After multivariable adjustment, Q1 to Q3 increments in MPA diameter and PA:Aodia were associated with mPAP increase of 12.5 [10.7, 14.4] and 13.9 [11.9, 15.8] mmHg, respectively. BMI showed no correlation with PA size (ρ = 0.076 for MPA area, -0.051 for PA:Aodia). Conclusions: PA size increases alongside PH severity using updated hemodynamic criteria and is associated with incremental increases in PA pressure and mortality. LPA dilation demonstrates particularly strong association with mortality. PA size does not correlate with BMI. These novel findings enhance our understanding of vascular changes across the PH disease spectrum.
Physical Activity, Sleep, and Quality of Life in Pulmonary Arterial Hypertension: Novel Insights From Wearable Devices
Hughes, Andrew , Lindsey, Alisha, Annis, Jeffrey , Burke, Kelly, Master, Hiral , Silverman-Lloyd, Luke G , Garry, Jonah , Hassoun, Paul M. , Larive, Brett , Hill, Nicholas S. , Erzurum, Serpil C. , Beck, Gerald J. , Hughes, Andrew M , Garry, Jonah D , Hemnes, Anna , Lindsey, Alisha, Blaha, Michael Joseph , Rosenzweig, Erika B. , Frantz, Robert P. , Hassoun, Paul M. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Hemnes, Anna R. , Brittain, Evan L

Mayo Clinic

Pulmonary Circulation | April 17, 2025 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/pul2.70069 | PMID 40248215 Get It

ABSTRACT Reduced functional capacity and poor sleep quality are common in pulmonary arterial hypertension (PAH). Wearable devices are an emerging, user‐friendly tool to capture activity and sleep information. We aimed to determine whether Fitbit‐derived activity and sleep trends provide clinically meaningful information in patients with PAH. Our prospective observational study recruited patients with PAH from across the United States using remote enrollment strategies and in‐person efforts. Participants wore a Fitbit device for 12 weeks at baseline and a subgroup with 1‐year follow‐up. A matched control cohort was generated from the All of Us Research Program and we evaluated changes in patients with PAH compared to matched controls. Among 110 patients with baseline monitoring, average daily steps correlated with 6MWD ( r = 0.61, p < 0.001) and percent rapid eye movement (REM) sleep ( r = 0.28, p = 0.008). In 44 PAH participants who completed baseline and 1‐year monitoring, there was a group‐time interaction for percent light sleep ( p = 0.024) and percent REM sleep ( p = 0.034), which demonstrated that sleep quality worsened in patients with PAH over 1 year compared to matched controls. Average daily steps decreased in patients with PAH from 5200 [IQR 3212–7458] at baseline to 4651 [IQR 2912–6827] at 1 year ( p = 0.008). In conclusion, our study demonstrated the potential clinical value of wearable devices by showing that activity and sleep quality are reduced in PAH compared to matched controls and these measures decline over time. Future studies should investigate if monitoring these health behaviors detects early functional decline and whether targeted interventions may improve outcomes.
Editorial on “Developing Benchmarks in the Diagnosis and Treatment of Pulmonary Arterial Hypertension in a Tertiary, Academic Medical Center”
Frantz, Robert P. , Frantz, Robert P

Mayo Clinic

Pulmonary Circulation | April 16, 2025 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/pul2.70081 | PMID 40241914 Get It

TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation and Fibrosis Improve with Treatment
Osterhout, Robin , Channick, Richard, Frantz, R, McLaughlin, V.V., Vachiéry, J, Roscigno, Robert F., Mottola, David, Sitapara, Ravi, Aranda, R., Zisman, Lawrence S. , Bruey, Jean‐Marie, Zamanian, R.T., Ghofrani, Hossein Ardeschir , Osterhout, Robin E. , Benza, Raymond L. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier , Sitapara, Ravikumar

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804783 Get It

Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Zolty, R., Kingrey, J.F. , Penn, Benjamin G., Sobol, Irina , Sood, Namita , Benza, R.L., Channick, Richard, Frantz, R, McLaughlin, V.V., Vachiéry, J, Zamanian, R.T., Cravets, Matt , Roscigno, Robert F., Mottola, David, Parsley, Ed, Aranda, R., Zisman, Lawrence S. , Ghofrani, Hossein Ardeschir , Sahay, Sandeep , Subías, Pilar Escribano , Penn, B, Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804612 Get It

Trial in Progress: PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension (PAH)
Held, Matthias , Benza, R.L., Channick, Richard, Chin, K. , Frantz, R, Howard, L, McLaughlin, Vallerie V. , Zamanian, R.T., Bruey, Jean‐Marie, Cravets, Matt , Mottola, David, Zisman, Lawrence S. , Parsley, Ed, Roscigno, Robert F., Aranda, R., Vachiéry, J, Sitbon, Olivier , Frantz, Robert P. , Ghofrani, Hossein Ardeschir , Hemnes, Anna R. , McLaughlin, Vallerie V.

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804609 Get It

Correlation of pulmonary artery systolic pressures derived from echocardiography and hemodynamic catheterization in patients with tricuspid regurgitation: a large single-center study
Pislaru, S, Kane, G C, Miranda, William R. , Anand, Vidhu , Pugliesi, G M, Frantz, Robert P.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 29, 2025 | Volume: 26 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjci/jeae333.433 Get It

Abstract Introduction Echocardiography is the recommended modality for non-invasive assessment of pulmonary pressures. However, in patients with severe tricuspid regurgitation (TR), the reliability of echocardiographically derived systolic pulmonary artery pressure (sPAP) is questioned. Limited data exists on the correlation between echocardiography and right heart catheterization (RHC) in selected group of patients with severe TR. Purpose To evaluate the correlation between echocardiographic and RHC measurements for sPAP in patients with varying TR severity. Method Patients who underwent echocardiography and RHC within three days at a large single referral center were retrospectively included. Exclusion criteria included incomplete echocardiographic and RHC data, ≥moderate pulmonary stenosis, low-quality images, and pregnancy. Echocardiographic sPAP was calculated using simplified Bernoulli equation. Echocardiographic right atrial pressure (RAP) was assessed by evaluating inferior vena cava (IVC) dimension and collapsibility. A difference of ≥10 mmHg between the two modalities for sPAP was considered clinically significant. Results Of 3696 patients included, mean age was 64±14 years, 1689 (46%) were females, 1659 (45%) had systemic hypertension, and 582 (16%) had atrial fibrillation. TR was &lt;moderate in 2475 (67%) patients, moderate in 499 (14%), moderate-severe in 277 (7%), and severe in 445 (12%). Pulmonary hypertension (PH) was diagnosed in 3079 subjects (83%). A good correlation was found between sPAP derived by echocardiographic and RHC in the whole cohort (correlation coefficient (LCC) 0.79, CI 0.78-0.80), in severe TR subgroup (LCC 0.78, CI 0.75-0.82), and in severe TR with PH subgroup (LCC 0.76, CI 0.71-0.79). The mean echocardiographic misestimation for sPAP in severe TR was 3.97 mmHg (CI -5.24 to -2.71). The correlation between the two modalities for RAP was moderate in the whole cohort (LCC 0.59, CI 0.57-0.61) and fair in severe TR (LCC 0.35, CI 0.27-0.42). A clinically significant difference between the two modalities for sPAP was found in 1504 patients (41%), predominantly due to the right ventricle-right atrium gradient misestimation, rather than RAP misestimation, in patients with no PH (67% vs 33%), patients with mild-moderate PH (mean Pulmonary Artery Pressure (mPAP) 21-34 mmHg) (67% vs 33%) and severe PH (mPAP ≥35 mmHg) (76% vs 24%). Conclusion The correlation between echocardiographic and RHC measurements is good for sPAP, even in severe TR patients, while it is only fair to moderate for RAP. A clinically significant difference between echocardiographic and RHC sPAP is more commonly observed in patients with PH, with right ventricle-right atrium gradient misestimation being the most common cause.